| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Avicularin is a naturally occurring flavonoid isolated from plants, with anti-inflammatory, anti-allergic, anti-oxidant, hepatoprotective, and anti-tumor activities. controls the activities of PPAR-γ, COX-2, and NF-κB (p65).
| Targets |
GLUT4; PPARγ; COX-2
|
|---|---|
| ln Vitro |
In LPS-stimulated RAW 264.7 cells, avicuLarin (10-300 μM, 1 hour) suppresses the generation of NO and PGE2 [1]. In LPS-stimulated RAW 264.7 cells, AvicuLarin (10-300 μM, 1 h) suppresses ERK signaling. In Huh7 cells, AvicuLarin (25-100 μg/mL, 48 h) decreases apex, proliferation, and cell migration [2]. By reporting NF, AvicuLarin (25-100 μg/mL, 48 h) demonstrates anti-inflammatory efficacy [1]. AvicuLarin (50 μM, 6 days) decreases 3T3-L1 cells, PPARγ, and C/EBPα in addition to intracellular toxins. -κB (p65) causes an increase in PPAR-γ and COX-2 expression as well as cell disinfection [2]. 3T3-L1 cells' quantitative dose-mediated GLUT4-mediated inhibition is inhibited by avicuLarin (50 μM, 6 days) [3]. AvicuLarin (2.5-10 μM, 2 hours) increases the amounts of aP2 mRNA in both human formulations and solutions [3].
|
| ln Vivo |
AvicuLarin, an intra-articular injection administered twice weekly for four weeks at a dose of 0.5-2 mg/kg, inhibits the progression of stent OA (osteoarthritis) caused by ACLT [4]. AvicuLarin (Laterolateralis, 50 and 100 mg/kg for 21 days) impairs memory in deposits of Alzheimer's disease caused by amyloid beta [5].
|
| Cell Assay |
Cell proliferation assay [2]
Cell Types: Huh7 cells Tested Concentrations: 25, 50, 100 μg/mL Incubation Duration: 12, 24, 36 and 48 h Experimental Results: Inhibition of cell proliferation was dose-dependent. Western Blot Analysis [1] Cell Types: RAW 264.7 Cell Tested Concentrations: 10, 30, 100, 300 μM Incubation Duration: 1 h Experimental Results: Inhibited LPS-induced iNOS and COX-2 protein expression, released pro-inflammatory cytokines IL-1β, Cytoplasmic IκB degradation and ERK phosphorylation. RT-PCR[3] Cell Types: 3T3-L1 Cell Tested Concentrations: 50 μM Incubation Duration: 6 days Experimental Results: PPARγ, C/EBPα and aP2 mRNA levels were diminished by approximately 28.7%, 69.5 and 18.3% respectively. |
| Animal Protocol |
Animal/Disease Models: ACLT (anterior cruciate ligament transection) induced rats [4]
Doses: 0.5, 1, 2mg/kg Route of Administration: Inject into the right knee joint cavity, twice a week for 4 weeks. Experimental Results: Reduce tibial subchondral osteolysis, reduce bone loss, and increase tibial subchondral bone mass. Attenuated ECM degradation and loss of aggrecan and type II collagen in ACLT-induced rats. diminished MMP3 and MMP13 protein levels. Animal/Disease Models: Rats with beta-amyloid-induced Alzheimer's disease [5] Doses: 25, 50 and 100 mg/kg Route of Administration: Orally for 21 days Experimental Results: Enhanced cognitive activity , reverses the effects of amyloid-induced inflammatory responses and excessive oxidative stress. |
| References |
[1]. Vo VA, et al. Avicularin Inhibits Lipopolysaccharide-Induced Inflammatory Response by Suppressing ERK Phosphorylation in RAW 264.7 Macrophages. Biomol Ther (Seoul). 2012 Nov;20(6):532-7.
[2]. Wang Z, et al. Avicularin ameliorates human hepatocellular carcinoma via the regulation of NF‑κB/COX‑2/PPAR‑γ activities. Mol Med Rep. 2019 Jun;19(6):5417-5423. [3]. Ko Fujimori, et al. Avicularin, a plant flavonoid, suppresses lipid accumulation through repression of C/EBPα-activated GLUT4-mediated glucose uptake in 3T3-L1 cells. J Agric Food Chem. 2013 May 29;61(21):5139-47. [4]. Zi-Ling Zou, et al. Avicularin suppresses cartilage extracellular matrix degradation and inflammation via TRAF6/MAPK activation. Phytomedicine. 2021 Oct;91:153657. [5]. Nikita Patil Samant, et al. Avicularin Attenuates Memory Impairment in Rats with Amyloid Beta-Induced Alzheimer's Disease. Neurotox Res. 2022 Feb;40(1):140-153. |
| Molecular Formula |
C₂₀H₁₈O₁₁
|
|---|---|
| Molecular Weight |
434.35
|
| Exact Mass |
434.0849
|
| Elemental Analysis |
C, 55.31; H, 4.18; O, 40.52
|
| CAS # |
572-30-5
|
| Related CAS # |
572-30-5
|
| Appearance |
Solid powder
|
| SMILES |
C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H](O4)CO)O)O)O)O
|
| InChi Key |
BDCDNTVZSILEOY-UXYNSRGZSA-N
|
| InChi Code |
InChI=1S/C20H18O11/c21-6-13-15(26)17(28)20(30-13)31-19-16(27)14-11(25)4-8(22)5-12(14)29-18(19)7-1-2-9(23)10(24)3-7/h1-5,13,15,17,20-26,28H,6H2/t13-,15-,17+,20-/m0/s1
|
| Chemical Name |
3-[(2S,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
|
| Synonyms |
Quercetin; 3-O-α-L-arabinofuranoside; Avicularin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~230.2 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3023 mL | 11.5115 mL | 23.0229 mL | |
| 5 mM | 0.4605 mL | 2.3023 mL | 4.6046 mL | |
| 10 mM | 0.2302 mL | 1.1511 mL | 2.3023 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
